Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma

Area of Science:

• Immunotherapy
• Oncology
• Biotechnology

Background:

• Metastatic melanoma has a poor prognosis with limited treatment options.
• Chondroitin sulfate proteoglycan 4 (CSPG4) is uniformly expressed on melanoma cells, making it a viable therapeutic target.
• Genetically-engineered T cell therapy, specifically chimeric antigen receptor (CAR) T cells, shows promise for treating metastatic melanoma.

Purpose of the Study:

• To investigate the potential of combining a chimeric co-stimulatory receptor (CCR) with a CSPG4-directed CAR T cell therapy.
• To enhance the anti-tumor efficacy of CAR T cells while minimizing off-tumor toxicity.
• To evaluate the therapeutic window for metastatic melanoma treatment using this combined approach.

Main Methods:

• Developed a moderate-potency, second-generation CSPG4-CAR T cell therapy.
• Engineered T cells to co-express a CCR lacking the CD3ζ activation element.
• Assessed the anti-tumor response of CSPG4-CAR T cells with and without CCR co-expression in vitro and in vivo.
• Investigated the effect of CCR-mediated trans-activation on CAR T cell response.

Main Results:

• Co-expression of CCR significantly enhanced the anti-tumor response of CSPG4-CAR T cells in vitro and in vivo.
• The observed boosting effect was independent of simultaneous target antigen expression on the same tumor cell.
• Trans-activation mediated by CCR effectively boosted CAR T cell activity.

Conclusions:

• Chimeric co-stimulatory receptors (CCRs) can significantly enhance the cytolytic potential of CAR T cells.
• This combined CCR-CAR T cell strategy offers a promising therapeutic approach for metastatic melanoma.
• The findings suggest a novel therapeutic window for enhancing T cell-based cancer immunotherapy.